The dose chosen in our study is expected to provide IL-17A exposure in the range described in pre-hypertensive patients (Yao et al., 2015) and suggests that low circulating IL-17A levels could be involved in the generation of hypertension. This evidence concerns the gene IL17A and hypertensive disorder.